Quanticate, a leading global data-focused Clinical Research Organization (CRO), has named Lee Patterson as the company’s Chief Operating Officer (COO).
Prior to Quanticate, Patterson served in global leadership positions at various pharma companies and CROs including; Covance, Pathfinder Protek, Sanofi and Biomen Diagnostics. In his new role, Patterson will work across Quanticate’s global office network (UK, North America, India, South Africa, and Poland).
With data-focused solutions growing in importance in response to the trend towards virtual and decentralised trials, patient centricity and more efficient monitoring techniques, Patterson will help guide and implement innovative tools, services and approaches with a constant focus on quality. His experience will support Quanticate in expanding its global footprint to meet growing client needs across the pharmaceutical, biotechnology and medical device sectors.
David Underwood, Chairman and CEO of Quanticate said: “I’m delighted to announce the appointment of Lee Patterson as our new COO. Quanticate has experienced strong growth in recent years and Lee’s expertise will enable us to grow further and ensure our reputation for being trusted by top pharmaceutical companies and delivering a high-quality service remains.
“Lee’s leadership over our operational teams will ensure the highest quality is delivered to our customers at all times and our leading position in the marketplace as a niche data-focused CRO is continually strengthened.”
Lee Patterson added: “I’m delighted to be stepping into the role of COO, taking the operations of Quanticate to new heights and building on the great success that the team at Quanticate has already made. With a focus on the high-quality service our customers expect, I am looking forward to driving our business operations forward and staying one step ahead of evolving needs.”